Efficacy & Safety of 980nm Diode Laser vs. Cryotherapy for Plantar Warts
Launched by FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR · Jan 19, 2024
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Background: Plantar warts are a common dermatological condition caused by human papillomavirus infection. They can be painful and negatively impact quality of life. Many treatments exist but there is lack of consensus on the optimal approach.
Objectives:
Primary objective: To compare the efficacy of 980nm diode laser versus liquid nitrogen cryotherapy for clearing plantar warts, as measured by the complete clearance rate at 4 weeks post-treatment.
Secondary objectives: To evaluate and compare pain levels during treatment procedures and adverse events between both groups.
Study design: R...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with recalcitrant, mosaic and simple HPV
- Exclusion Criteria:
- • Diabetic, ischaemic and immunosuppressed patients
- • Patients with cold intolerance
- • Patients with any of the following conditions (blood dyscrasias of unknown origin, cryoglobulinaemia, cryofibrinogenemia, collagen or autoimmune disease)
- • Patients who do not sign the informed consent form.
About Fundación Universidad Católica De Valencia San Vicente Mártir
Fundación Universidad Católica de Valencia San Vicente Mártir is a prominent academic institution dedicated to advancing healthcare through innovative research and education. As a clinical trial sponsor, it leverages its robust medical and scientific expertise to conduct high-quality clinical studies aimed at improving patient outcomes and contributing to the advancement of medical knowledge. The foundation is committed to ethical research practices and collaboration with healthcare professionals, ensuring that its trials adhere to the highest standards of regulatory compliance and scientific integrity. Through its initiatives, it strives to foster a culture of excellence in clinical research and enhance the well-being of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Catania, Sicilia, Italy
Valencia, València, Spain
Patients applied
Trial Officials
Javier Ferrer-Torregrosa, Dr.
Study Director
FundaciónUcv
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported